Directorio

We will schedule you to attend 3 in-person study visits over the course of 6 months. The visits will take place either in Durham, NC or Kannapolis, NC. Each visit involves functional testing, having a small blood draw and providing a urine sample, completing a brief pain assessment, and answering questionnaires about your pain experiences and general wellbeing. After 12 months, we will ask you to fill out some additional questionnaires online.

We are doing this study to find the most effective, safe dose of an experimental drug called iadademstat (the study drug). We want to know if the study drug is beneficial for people with R/R AML that have the FLT3 mutation when it is given in combination with gilteritinib.

We are doing this study to find out if anti-HER2 treatment can be safely stopped in patients with metastatic HER2+ breast cancer who have had an exceptional response to treatment for at least 3 years.

We are doing this study to find out if an ophthalmic insert called Dextenza can be used to control eye inflammation and pain in pediatric patients after routine retinal surgery or laser treatment.

We are doing this study to learn more about the effects of exercise and medication on symptoms of worry and stress in adults with heart disease. This study is important because symptoms of worry and stress are risk factors for worsening heart health.

We are doing this to compare the results of early surgical intervention to medical therapy. We want to know if there is a difference in outcomes for these treatment options. We also want to track the health and progress of people with a large ascending aortic aneurysm (a bulge in the aorta caused by weakening in the artery wall).

We are doing this study to see how an experimental drug called evolocumab (study drug) works in your body and against your cancer when it is given in combination with approved immunotherapy drugs.

We are doing this research study to learn about the safety and effectiveness of alirocumab (a cholesterol-lowering drug) when it is combined with cemiplimab (an immunotherapy drug) and preoperative chemotherapy in patients with stage 1B-3A non-small cell lung cancer (NSCLC) who will undergo surgery. This study is important because it might potentially improve outcomes for you and other future patients.